Cerus Corporation

Cerus Corporation to Participate in 21st Annual Craig-Hallum Institutional Investor Conference

Retrieved on: 
Mercoledì, Maggio 22, 2024
Medical Supplies, Health, Hospitals, Health Technology, Cardiology, Biotechnology, Corporation, Cerus Corporation, CERS, Conference

Cerus Corporation (Nasdaq: CERS) announced today that Kevin Green, Cerus’ chief financial officer, is scheduled to participate at the 21st Annual Craig-Hallum Institution Investor Conference in Minneapolis, on Wednesday, May 29th.

Key Points: 

Cerus Corporation (Nasdaq: CERS) announced today that Kevin Green, Cerus’ chief financial officer, is scheduled to participate at the 21st Annual Craig-Hallum Institution Investor Conference in Minneapolis, on Wednesday, May 29th.

Cerus Corporation Announces First Quarter 2024 Financial Results

Retrieved on: 
Giovedì, Maggio 2, 2024
Medical Supplies, Health, Medical Devices, Hospitals, Health Technology, General Health, Biotechnology, FDA, Red blood cell, Investment, AUC, Cerus Corporation, Research, Canadian Blood Services, LED, Patient, Platelet, Government, GAAP, Growth, Pharmaceutical industry

The Company expects to report GAAP net loss attributable to Cerus Corporation for the full-year 2024 while also remains committed to adjusted EBITDA breakeven for the full-year 2024.

Key Points: 
  • The Company expects to report GAAP net loss attributable to Cerus Corporation for the full-year 2024 while also remains committed to adjusted EBITDA breakeven for the full-year 2024.
  • R&D expenses for the first quarter of 2024 were $14.5 million, compared to $17.4 million for the first quarter of 2023.
  • Net loss attributable to Cerus Corporation for the first quarter of 2024 was $9.7 million, or $0.05 per basic and diluted share, compared to a net loss attributable to Cerus Corporation of $15.6 million, or $0.09 per basic and diluted share, for the first quarter of 2023.
  • As discussed during prior quarters, the Company expects full-year 2024 non-GAAP adjusted EBITDA breakeven, though over the near term, results may not be consistent quarter by quarter.

Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024

Retrieved on: 
Giovedì, Aprile 18, 2024
Medical Supplies, Health, Hospitals, Health Technology, Other Health, Biotechnology, Cerus Corporation, Corporation, Webcast, CERS

Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2024 financial results will be released on Thursday, May 2, 2024, after the close of the stock market.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2024 financial results will be released on Thursday, May 2, 2024, after the close of the stock market.
  • ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.
  • To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com.
  • A replay will be available on Cerus’ website and will be available approximately three hours after the call through May 23, 2024.

Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life

Retrieved on: 
Martedì, Marzo 26, 2024
General Health, FDA, Medical Devices, Health, Cardiology, Corporation, CERS, Food, Cerus Corporation, Pharmaceutical industry

Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately.
  • This approval extends the set shelf life by six months from the existing six-month shelf life that took effect following a set component change last year.
  • All INTERCEPT Platelet Processing Sets in both customer and Cerus inventories are now eligible for this six-month extension.
  • This shelf-life extension applies to all sizes of INTERCEPT Platelet Processing Sets currently available in the U.S.
    “We are pleased with this successful and timely outcome to our regulatory filing with the FDA to re-establish a longer shelf life for INTERCEPT Platelet Processing Sets in the U.S.,” said Vivek Jayaraman, Cerus’ chief operating officer.

Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients

Retrieved on: 
Martedì, Marzo 19, 2024
Medical Supplies, Biotechnology, Practice Management, Other Health, Health, General Health, Health Technology, Medical Devices, Hospitals, Surgery, Clinical Trials, Red blood cell, STARS, Platelet, SPARC, Incidence, AKI, Patient, Corporation, Mitt, News, CERS, RBC, Acute kidney injury, Clinical trial, Antibody, Transfusion medicine, PMA, Safety, DSMB, Data, Food, FDA, Physician, Cerus Corporation, Pharmaceutical industry

Cerus Corporation (Nasdaq: CERS) today announced positive topline results for ReCePI, a pivotal Phase 3 clinical trial of pathogen reduced INTERCEPT Red Blood Cells (INTERCEPT RBCs) transfused to complex cardiac surgery patients.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) today announced positive topline results for ReCePI, a pivotal Phase 3 clinical trial of pathogen reduced INTERCEPT Red Blood Cells (INTERCEPT RBCs) transfused to complex cardiac surgery patients.
  • There was no clinical significance related to treatment-emergent RBC antibodies observed in five patients receiving INTERCEPT RBCs.
  • This safety endpoint is also being explored in the Company’s ongoing RedeS Phase 3 clinical trial of INTERCEPT RBCs.
  • “We are extremely pleased by the positive topline results of the ReCePI clinical trial,” stated Richard Benjamin, M.D., Ph.D., Cerus’ chief medical officer and principal investigator for the ReCePI clinical trial.

Cerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Martedì, Marzo 5, 2024
Medical Supplies, Health, Hospitals, Health Technology, Other Health, General Health, Biotechnology, Red blood cell, Investment, Growth, Government, Adjustment, Cerus Corporation, Research, Pharmaceutical industry

Product gross margin for the fourth quarter of 2023 was relatively stable year over year at 55.5% compared to 55.7% for the fourth quarter of 2022.

Key Points: 
  • Product gross margin for the fourth quarter of 2023 was relatively stable year over year at 55.5% compared to 55.7% for the fourth quarter of 2022.
  • R&D expenses for the fourth quarter of 2023 were $14.3 million, compared to $18.6 million for the fourth quarter of 2022.
  • Selling, general, and administrative (SG&A) expenses narrowed for the fourth quarter of 2023 and totaled $17.3 million, compared to $23.2 million for the fourth quarter of 2022.
  • Net loss attributable to Cerus Corporation for the fourth quarter of 2023 was $1.3 million, or $0.01 per basic and diluted share, compared to a net loss attributable to Cerus Corporation of $13.6 million, or $0.08 per basic and diluted share, for the fourth quarter of 2022.

Microsize Announces Expanded CDMO Relationship with Cerus Corporation

Retrieved on: 
Lunedì, Febbraio 26, 2024
Health, Manufacturing, Other Science, General Health, Other Manufacturing, Science, Cerus Corporation, News, Automation, Trust, History, Investment, Vaccine

The new supply agreement includes a joint CAPEX investment to build additional dedicated manufacturing suite capacity in 2023 and to qualify a higher-throughput processing train.

Key Points: 
  • The new supply agreement includes a joint CAPEX investment to build additional dedicated manufacturing suite capacity in 2023 and to qualify a higher-throughput processing train.
  • These investments will allow Cerus to support existing and future demand for INTERCEPT-treated blood components including plasma and cryoprecipitate.
  • The trust and collaboration between our companies has been enduring, and we look forward to continued expansion of this relationship.”
    ”We are delighted to continue our relationship with Microsize with today’s news.
  • “We are grateful to Microsize for helping us to execute on our mission to safeguard the global blood supply.”

Cerus Corporation to Release Fourth Quarter and Full-Year 2023 Financial Results on March 5, 2024

Retrieved on: 
Martedì, Febbraio 20, 2024
Biotechnology, General Health, Hospitals, Health, Medical Supplies, Cerus Corporation, CERS, Corporation, Webcast

Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2023 financial results will be released on Tuesday, March 5, 2024, after the close of the stock market.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2023 financial results will be released on Tuesday, March 5, 2024, after the close of the stock market.
  • ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.
  • To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com.
  • A replay will be available on Cerus’ website and will be available approximately three hours after the call through March 19, 2024.

Cerus Corporation to Participate in Upcoming Investor Conferences

Retrieved on: 
Giovedì, Febbraio 1, 2024
Research, Medical Devices, Public Relations, Investor Relations, Communications, Health Technology, Health, General Health, Other Science, Science, CERS, Digital health, Corporation, Cerus Corporation, Conference

Cerus Corporation (Nasdaq: CERS) announced management participation in two upcoming investor conferences.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) announced management participation in two upcoming investor conferences.
  • Management plans to attend the BTIG 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 13th and will participate in TD Cowen’s 44th Annual Health Care Conference on Wednesday, March 6th at 11:10 AM EST.
  • A live webcast of the TD Cowen presentation will be available here and the replay will be available on the Company’s website after the event.

Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2023 Product Revenue and Provides Business Update

Retrieved on: 
Lunedì, Gennaio 8, 2024
Biotechnology, General Health, Hospitals, Health, Medical Supplies, CE marking, Growth, Corporation, RBC, CERS, Cerus Corporation

Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2023 and provided product revenue guidance for full-year 2024.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2023 and provided product revenue guidance for full-year 2024.
  • Cerus’ unaudited preliminary product revenue for the fourth quarter of 2023 totaled $46.8 million, representing an increase of 6% over the $44.0 million recognized during the fourth quarter of 2022 and 18% sequentially.
  • The Company expects its unaudited preliminary full-year 2023 product revenue to be $156.4 million, in line with the Company’s 2023 product revenue guidance range of $155-$158 million.
  • “Additionally, we continue to expect to realize adjusted EBITDA breakeven for the fourth quarter 2023 when we report complete fourth quarter 2023 and year-end results,” continued Greenman.